Published in Law and Health Weekly, July 2nd, 2005
ADDVANCE intends to commit capital of up to $50 million over the next 3 years to development stage companies and new enterprises.
ADDVANCE partners and employees, working together with Angiotech scientists and clinicians, will explore novel commercialization avenues for Angiotech technology and intellectual property outside of Angiotech's core therapeutic areas of interest.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.